LZAP, a Putative Tumor Suppressor, Selectively Inhibits NF-κB

Cancer Cell

Volumn 12, Issue 3, 2007, Pages 239-251

  Wang, Jialiang ^a,b   An, Hanbing ^b   Mayo, Marty W ^d   Baldwin, Albert S ^e   Yarbrough, Wendell G ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

SIGNALING

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; CARISOPRODOL; GELATINASE B; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; PROTEIN LZAP; PROTEIN P53; PROTEIN SERINE 536; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE TRANSLOCATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR VASCULARIZATION; XENOGRAFT;

EID: 34548236254     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.07.002     Document Type: Article

References (28)

1. Ahuja D., Saenz-Robles M.T., and Pipas J.M. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24 (2005) 7729-7745
2. Ashburner B.P., Westerheide S.D., and Baldwin Jr. A.S. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21 (2001) 7065-7077
3. Bond M., Fabunmi R.P., Baker A., and Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-κB. FEBS Lett. 435 (1998) 29-34
4. Chang A.A., and Van Waes C. Nuclear factor-κB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv. Otorhinolaryngol. 62 (2005) 92-102
5. Chen F. Endogenous inhibitors of nuclear factor-κB, an opportunity for cancer control. Cancer Res. 64 (2004) 8135-8138
6. Chen L.F., and Greene W.C. Shaping the nuclear action of NF-κB. Nat. Rev. Mol. Cell Biol. 5 (2004) 392-401
7. Chung C.H., Parker J.S., Ely K., Carter J., Yi Y., Murphy B.A., Ang K.K., El-Naggar A.K., Zanation A.M., Cmelak A.J., et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 66 (2006) 8210-8218
8. Fingleton B. Matrix metalloproteinases: Roles in cancer and metastasis. Front. Biosci. 11 (2006) 479-491
9. Hayden M.S., and Ghosh S. Signaling to NF-κB. Genes Dev. 18 (2004) 2195-2224
10. He C. Molecular mechanism of transcriptional activation of human gelatinase B by proximal promoter. Cancer Lett. 106 (1996) 185-191
11. Hoberg J.E., Yeung F., and Mayo M.W. SMRT derepression by the IκB kinase α: A prerequisite to NF-κB transcription and survival. Mol. Cell 16 (2004) 245-255
12. Jiang H., Luo S., and Li H. Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint. J. Biol. Chem. 280 (2005) 20651-20659
13. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-κB in cancer: From innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
14. Kim H., and Koh G. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-κB-dependent pathway. Biochem. Biophys. Res. Commun. 269 (2000) 401-405
15. Kim H.J., Hawke N., and Baldwin A.S. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ. 13 (2006) 738-747
16. Liu X., Yuan H., Fu B., Disbrow G.L., Apolinario T., Tomaic V., Kelley M.L., Baker C.C., Huibregtse J., and Schlegel R. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J. Biol. Chem. 280 (2005) 10807-10816
17. Magal S.S., Jackman A., Ish-Shalom S., Botzer L.E., Gonen P., Schlegel R., and Sherman L. Downregulation of Bax mRNA expression and protein stability by the E6 protein of human papillomavirus 16. J. Gen. Virol. 86 (2005) 611-621
18. Mantovani F., and Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20 (2001) 7874-7887
19. Perkins N.D. Regulation of NF-κB by atypical activators and tumour suppressors. Biochem. Soc. Trans. 32 (2004) 936-939
20. Rocha S., Campbell K.J., and Perkins N.D. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol. Cell 12 (2003) 15-25
21. Rocha S., Garrett M.D., Campbell K.J., Schumm K., and Perkins N.D. Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 24 (2005) 1157-1169
22. Takada Y., Andreeff M., and Aggarwal B.B. Indole-3-carbinol suppresses NF-κB and IκBα kinase activation, causing inhibition of expression of NF-κB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 106 (2005) 641-649
23. Viatour P., Merville M.P., Bours V., and Chariot A. Phosphorylation of NF-κB and IκB proteins: Implications in cancer and inflammation. Trends Biochem. Sci. 30 (2005) 43-52
24. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
25. Wang J., He X., Luo Y., and Yarbrough W.G. A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2. Biochem. J. 393 (2006) 489-501
26. Westbrook T.F., Martin E.S., Schlabach M.R., Leng Y., Liang A.C., Feng B., Zhao J.J., Roberts T.M., Mandel G., Hannon G.J., et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 121 (2005) 837-848
27. Ying H., and Xiao Z.X. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle 5 (2006) 506-508
28. Zhang Y., Xiong Y., and Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92 (1998) 725-734